QIAGEN Partners With Maccura to Localize and Commercialize GeneReader NGS System in China

Tuesday, May 2, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

HILDEN, Germany, and CHENGDU, China, May 2, 2017 /PRNewswire/

--

Partnership with a leading Chinese IVD company with goal to accelerate penetration of the world's first complete Sample to Insight NGS solution in rapidly growing

Chinese market 

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the formation of a joint venture with Maccura Biotechnology Co., Ltd., a leading in vitro diagnostics (IVD) company in China. The joint venture, named MAQGEN plans to accelerate local adaptations, development and commercialization of the GeneReader NGS System in the rapidly growing clinical and clinical research markets in China. QIAGEN's GeneReader NGS System is the world's first complete Sample to Insight solution and makes the benefits of next-generation sequencing (NGS) accessible to any laboratory.

"We are very pleased to have formed this partnership with Maccura. The creation of MAQGEN lays the foundation to significantly accelerate and expand the availability of the GeneReader system in laboratories across China, thereby offering a state-of-the-art, seamlessly integrated NGS workflow with menu and other adaptations for the local market. China is the fastest-growing NGS market, and Maccura is China's fastest-growing major IVD company. Our strategy to work 'In China, With China' will boost both companies' presence in the IVD market in China," said Thierry Bernard, Senior Vice President and Head of QIAGEN's Molecular Diagnostics Business Area.

Click here for the full press release.

https://www.qiagen.com/about-us/press-releases/pressreleaseview?ID={F6E8DD20-9ED8-4E45-8436-E867CF8228F1}&lang=en

Contacts: QIAGEN Investor Relations     John Gilardi     +49-2103-29-11711 e-mail: [email protected] Public Relations Dr. Thomas Theuringer +49-2103-29-11826 e-mail: [email protected]

SOURCE QIAGEN N.V.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook